The Finnish maker of the Oura health-tracking finger ring is sponsoring a two-pronged, AI-aided COVID-19 study at the University of California, San Francisco (UCSF).

The idea is to initially place the device in medical waiting areas, from where it would help prepare staff for caseload ebbs and flows. Later it might be set in larger public spaces, helping to monitor epidemiological trends at the population level.

Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus.

Another healthcare company is leveraging AI to address the new coronavirus pandemic and help identify potential patients who could have the virus.

As the U.S. continues ramping up its response to the new coronavirus, COVID-19, the role of AI could loom large in helping identify the highest risk patients.

AI could provide radiologists with significant value as an advanced peer review tool, according to new findings published in Academic Radiology.

AI algorithms can improve the overall quality of breast cancer screenings, according to a new study published in JAMA Network Open.

TeraRecon announced Monday, March 2, that its AI solutions have been awarded two technology patents from the U.S. Patent and Trademark Office.

AI is expected to impact radiology more than perhaps any other medical specialty. In healthcare, though, nothing is a given.

Ping An has launched a new AI-powered system for evaluating CT scans for signs of the Wuhan coronavirus, or COVID-19.

Qure.ai, a Mumbai-based AI startup, raised $16 million in a recent funding round.

Researchers have developed a cost-effective technique for breast cancer screening that does not require radiation exposure.